Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.56 |
| ▸ | REN | P00797 | 11/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556538 | 0.91 | REN (0.68) | KCNH2RENCYP3A4CD274 | |
| SCHEMBL556663 | 0.83 | KCNH2 (0.60) | KCNH2RENSCN9ACYP3A4CD274 | |
| SCHEMBL556638 | 0.82 | REN (0.82) | KCNH2RENSCN9ACYP3A4 | |
| SCHEMBL557671 | 0.77 | REN (0.60) | KCNH2RENCYP3A4 | |
| SCHEMBL556611 | 0.76 | REN (0.59) | KCNH2RENCYP3A4 | |
| SCHEMBL7872419 | 0.76 | REN (0.72) | KCNH2RENSCN9ACYP3A4 | |
| SCHEMBL557192 | 0.76 | REN (0.59) | KCNH2RENCYP3A4 | |
| SCHEMBL556138 | 0.75 | REN (0.58) | KCNH2RENCYP3A4CD274 | |
| SCHEMBL556434 | 0.74 | REN (0.56) | KCNH2RENCYP3A4 | |
| SCHEMBL556537 | 0.74 | KCNH2 (0.72) | KCNH2RENSCN9ACYP3A4SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | KCNH2 1198/4885REN 1/4885SCN9A 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.